Table 5 Risk stratification according to ASCO/EORTC guidelines and extent of prophylactic administration of G-CSF

From: A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings

 

Patients to be considered for G-CSF according to ASCO/EORTC guidelines

Number of eligible patients receiving G-CSF (%)

Advanced disease

39

5 (13)

Regimen with 10–20% risk of febrile neutropenia and age ≥65

14

3 (21)

Regimen with 10–20% risk of febrile neutropenia and previous neutropenic event

14

5 (35)

Regimen >20% risk for febrile neutropenia

23

10 (43)

  1. Abbreviations: ASCO=American Society of Clinical Oncology; EORTC=European Organisation of Research and Treatment of Cancer; G-CSF=granulocyte colony-stimulating factor.
Back to article page